Ruxolitinib impairs migratory behavior of DCs. (A) Ruxolitinib-treated and LPS-stimulated human moDCs (▪) were assessed for their migratory behavior toward CCL19/MIP-3β in Transwell assays. □, Results of vehicle-exposed, LPS-stimulated DCs. Results are from 1 experiment representative of at least 3. The significance was calculated according to 1-way ANOVA Dunnett’s multiple comparison test and is related to the vehicle control. *P < .1; **P < .01; ***P < .001. (B) Overnight ruxolitinib-exposed, CFSE-labeled ex vivo–generated immature bmDCs (▪) were subcutaneously injected into the hock of TBI-FIA (M tuberculosis in FIA)–injected recipient mice together with vehicle-challenged, eFluor670-labeled immature bmDCs (□) and then quantified in the local draining lymph node by FACS. Both bmDC groups were further injected into solvent-injected recipients (“unprimed”) as control for spontaneous migration. Untreated (no ruxolitinib, no vehicle exposure), but CFSE- or eFluor670-labeled bmDCs were used as additional controls to exclude changes in migratory behavior due to the dying process (“untreated”). Numbers indicate percentage of migrated bmDCs of all lymph node cells. (C) Histograms represent results of pooled independent experiments with a total of n = 14 (10 µM), n = 8 (5 µM), n = 7 (1 µM) mice. The significance was calculated according to the Mann-Whitney test and is related to the vehicle control. *P < .1; **P < .01; ***P < .001.